Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized,Controlled,Open-label,Prospective,Single-center Study to Investigate the Neoadjuvant Therapy of SHR-1210 in Combination With Carboplatin and Paclitaxel-albumin in Combination With Carboplatin and Paclitaxel in Resectable NSCLC

NCT04108013 is registered in ClinicalTrials.gov with Xuanwu Hospital, Beijing as lead sponsor.

NCT NCT04108013
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04108013 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized,Controlled,Open-label,Prospective,Single-center Study to Investigate the Neoadjuvant Therapy of SHR-1210 in Combination With Carboplatin and Paclitaxel-albumin in Combination With Carboplatin and Paclitaxel in Resectable NSCLC
Lead sponsor
Xuanwu Hospital, Beijing
Phase
Phase 2
Overall status
Unknown status
Start date
October 8, 2019
Completion date
July 31, 2021
Enrollment
38 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer stage ii, non-small cell lung cancer, pd-1 antibody